PTE Stock Soars 70% Following PolarityTE’s New FDA Designation

PolarityTE (NASDAQ:PTE) stock is rocketing higher on Friday thanks to positive news from the U.S. Food and Drug Administration (FDA).

colorful pills and vials sitting on a table representing PTE stock.

Source: Bukhta Yurii /

The big news here is the FDA granting Regenerative Medicine Advanced Therapy (RMAT) designation for the company’s SkinTE product. SkinTE is an investigational new drug in development to treat chronic cutaneous ulcers.

According to PolarityTE, this new RMAT designation will allow it to move forward with testing of the treatment in clinical trials. It should also speed up the company’s approval process and aid it in manufacturing the product for commercial use.

Richard Hague, CEO of PolarityTE, had the following to say in the news release sending PTE stock higher today.

“FDA granting our request for an RMAT designation for SkinTE validates not only the strength of the preliminary clinical evidence we have developed to date but also demonstrates the seriousness of the conditions that we seek to treat and the substantial nature of the unmet needs among the patient populations that we aim to serve.”

Today’s news brings with it heavy trading of PTE stock. This has some 53 million shares on the move as of this writing. That’s quite the jump over the company’s daily average trading volume of about 6.5 million shares.

PTE stock is up 48% as of Friday morning.

Investors seeking out more stock market news for today are in the right place!

InvestorPlace houses all of the latest stock market news traders need to know about on Friday. A few examples include what has shares of Figs (NYSE:FIGS) stock, Robinhood (NASDAQ:HOOD) stock, and Mullen Automotive (NASDAQ:MULN) stock on the move today. You can catch up on all of that news with the links below!

More Friday Stock Market News

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that’s writers disclose this fact and warn readers of the risks. 

Read More:Penny Stocks — How to Profit Without Getting Scammed

Article printed from InvestorPlace Media,

©2023 InvestorPlace Media, LLC